ARS Pharmaceuticals (SPRY) Cash from Investing Activities (2020 - 2026)

ARS Pharmaceuticals has disclosed Cash from Investing Activities across 7 years of filings, most recently posting $27.8 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $27.8 million, down 4.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $55.5 million (up 180.99% YoY), and the FY2025 annual result was $56.8 million, up 153.5% from the prior year.
• Cash from Investing Activities came in at $27.8 million for Q1 2026 at ARS Pharmaceuticals, up from $24.1 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $48.6 million in Q2 2025 to a low of -$111.5 million in Q1 2023.
• The 5-year median for Cash from Investing Activities is -$22000.0 (2022), against an average of -$6.4 million.
• Peak annual rise in Cash from Investing Activities reached 204509.09% in 2023, while the deepest fall reached 531071.43% in 2023.
• ARS Pharmaceuticals' Cash from Investing Activities stood at -$126000.0 in 2022, then jumped by 20765.87% to $26.0 million in 2023, then slumped by 490.8% to -$101.8 million in 2024, then surged by 123.7% to $24.1 million in 2025, then gained by 15.25% to $27.8 million in 2026.
• The last three Cash from Investing Activities figures came in at $27.8 million (Q1 2026), $24.1 million (Q4 2025), and -$45.0 million (Q3 2025), per Business Quant data.